Beta-endorphin-like immunoreactivity: assessment of blood levels in patients with tumors of different origin.
Beta-endorphin-like immunoreactivity (beta-ELIR) blood levels in control subjects and in patients with different carcinoma and non-Hodgkin's lymphoma tumor types, were found within the same range, with the exception of one carcinoma type. This pertained to a group of patients with small cell lung cancer who had a significantly higher median beta-ELIR level compared to controls. This finding, and the fact that proopiomelanocortin expression is enhanced in tissues of this cancer type, suggest that the latter might secrete elevated beta-ELIR amounts into the blood of the affected patients.
Pasi
A
A
Endorphin Laboratories, Institute of Forensic Medicine, University of Zurich, Switzerland.
Amsler
U
U
Messiha
F S
FS
D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000097:blood*; D001615:beta-Endorphin / Q000097:blood* / Q000276:immunology
D001615:beta-Endorphin